Barclays lowered the firm’s price target on Xylem (XYL) to $154 from $156 and keeps an Overweight rating on the shares. The company reported Q1 results in line with guidance and reiterated fiscal 2026 organic growth and margin expectations, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XYL:
- Xylem Inc. Balances Margin Gains With China Drag
- Analyst Reiterates Buy on Xylem After Q1 Beat, Raised Revenue Outlook, and Strong Water Metering Momentum
- Xylem reports Q1 adjusted EPS $1.12, consensus $1.08
- Xylem sees 2026 adjusted EPS $5.35-$5.60, consensus $5.49
- XYL Upcoming Earnings Report: What to Expect?